A Compelling Risk/Reward Seen In Momenta Pharmaceuticals By: Benzinga via Benzinga October 11, 2016 at 14:01 PM EDT Barclays sees a compelling risk/reward in Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) citing the Copaxone 40mg trial. The firm sees ... Read More >> Related Stocks: Momenta Pharma